Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAZ954 + spartalizumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**KAZ954 + spartalizumab** is an investigational combination therapy of two monoclonal antibodies for advanced solid tumors. KAZ954 is a monoclonal antibody targeting ENTPD2 (Ectonucleoside triphosphate diphosphohydrolase 2), which modulates the tumor microenvironment by regulating extracellular nucleotide levels and immune cell activity. By blocking ENTPD2, KAZ954 can stimulate anti-tumor T cell responses. Spartalizumab (PDR001) is an anti-PD-1 immune checkpoint inhibitor designed to enhance the immune system’s ability to recognize and kill cancer cells by blocking the PD-1 protein on T cells. The combination is being studied for potential enhanced immunomodulatory and anti-cancer effects versus monotherapy[1][3].
- Other names
- KAZ954 + PDR001
02
Targets
ENTPD2 (Ectonucleoside triphosphate diphosphohydrolase 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on KAZ954 + spartalizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAZ954 + spartalizumab.